Bloomberg -- Roche Holding AG will this year ask U.S. health regulators to approve its T-DM1 experimental breast cancer treatment, a medicine the company says may generate more than 2 billion Swiss francs ($1.89 billion) in annual sales.
Bloomberg -- Roche Holding AG will this year ask U.S. health regulators to approve its T-DM1 experimental breast cancer treatment, a medicine the company says may generate more than 2 billion Swiss francs ($1.89 billion) in annual sales.
